Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Viruses ; 16(3)2024 03 06.
Artigo em Inglês | MEDLINE | ID: mdl-38543770

RESUMO

In GEMINI-1/-2, dolutegravir + lamivudine was non-inferior to dolutegravir + tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in achieving viral suppression (viral load [VL] < 50 copies/mL) in treatment-naive adults. Abbott's RealTime HIV-1 assay provides quantitative VL (40-10,000,000 copies/mL) and qualitative target detected or target not detected (TND) for VL < 40 copies/mL. This post hoc analysis assessed very-low-level viremia and "blips" through Week 144. Proportions with VL < 40 copies/mL and TND are presented overall and by baseline VL and CD4+ cell count. "Blips" (single VL ≥ 50 to <200 copies/mL with adjacent values < 50 copies/mL) were assessed from Day 1 after VL suppression and from Weeks 48 through to 144. Proportions with TND increased through Week 48 and were similar between groups at all visits (Week 144: dolutegravir + lamivudine, 451/716 [63%]; dolutegravir + TDF/FTC, 465/717 [65%]). By observed analysis, TND rates were similar between groups across baseline subgroups. Through Week 144, proportions with ≥1 "blip" were generally comparable for dolutegravir + lamivudine vs. dolutegravir + TDF/FTC from Day 1 (15% vs. 20%) and from Week 48 (7% vs. 11%). Through 144 weeks, the proportions with TND or "blips" were similar between dolutegravir + lamivudine and the three-drug comparator, reinforcing the efficacy and durability of dolutegravir + lamivudine.


Assuntos
Fármacos Anti-HIV , Infecções por HIV , Soropositividade para HIV , HIV-1 , Oxazinas , Piperazinas , Piridonas , Adulto , Humanos , Lamivudina/uso terapêutico , Emtricitabina/uso terapêutico , Tenofovir/uso terapêutico , Infecções por HIV/tratamento farmacológico , Fármacos Anti-HIV/uso terapêutico , Quimioterapia Combinada , Compostos Heterocíclicos com 3 Anéis/uso terapêutico , Carga Viral , Replicação Viral
2.
Viruses ; 15(12)2023 12 14.
Artigo em Inglês | MEDLINE | ID: mdl-38140667

RESUMO

After a decade of dolutegravir (DTG) use in various antiretroviral therapy combinations and in diverse populations globally, it is critical to identify HIV strains with reduced drug susceptibility and monitor emergent resistance in people living with HIV who experience virologic failure while on DTG-based regimens. We searched the PubMed, Embase, and Cochrane databases to identify studies that reported DTG resistance-associated mutations (RAMs) emerging under selection pressure. Our review showed that RAMs conferring resistance to DTG were rare in 2-drug and 3-drug regimens used in real-world cohorts, corroborating data from clinical trials. The potency of DTG in maintaining virologic suppression was demonstrated, even in cases of pre-existing resistance to companion drugs in the regimen. Estimates of DTG RAMs depended on the population and certain risk factors, including monotherapy, baseline resistance or lack of genotypic testing, treatment history and prior virologic failure, and suboptimal treatment adherence. The RAMs detected after virologic failure, often in heavily treatment-experienced individuals with prior exposure to integrase strand transfer inhibitors, were G118R, E138K, G140A/C/R/S, Q148H/K/R, N155H, and R263K. Overall, these data highlight the durable effectiveness and high barrier to resistance of DTG as part of combination antiretroviral therapy in a wide variety of settings.


Assuntos
Infecções por HIV , Inibidores de Integrase de HIV , Integrase de HIV , Humanos , Inibidores de Integrase de HIV/farmacologia , Inibidores de Integrase de HIV/uso terapêutico , Integrase de HIV/genética , Infecções por HIV/tratamento farmacológico , Compostos Heterocíclicos com 3 Anéis/farmacologia , Compostos Heterocíclicos com 3 Anéis/uso terapêutico , Farmacorresistência Viral/genética , Mutação
3.
Adv Physiol Educ ; 37(1): 61-4, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23471250

RESUMO

We examined whether requiring an individual readiness assurance test (iRAT) before a team readiness assurance test (tRAT) would benefit students in becoming better problem solvers in physiology. It was tested in the form of tRAT scores, the time required to complete the tRAT assignment, and individual performance on the unit examinations. Students in one section were given the iRAT at the beginning of the team-based learning session. The same set of questions was given to students as their tRAT immediately after their iRAT. Students in the second section were not given the iRAT before the tRAT. This pattern was reversed for the next scheduled team-based learning activity between the two sections. We found that the section having both the iRAT and tRAT scored higher on the tRAT and completed their assignments in less time than the section with the tRAT alone. This suggests that the tRAT combined with the iRAT is an effective team-based approach to the teaching of physiology compared with the tRAT alone.


Assuntos
Educação em Farmácia/métodos , Avaliação Educacional/métodos , Processos Grupais , Fisiologia/educação , Aprendizagem Baseada em Problemas/métodos , Estudantes , Currículo/normas , Educação em Farmácia/normas , Avaliação Educacional/normas , Feminino , Humanos , Aprendizagem , Masculino , Fisiologia/normas , Aprendizagem Baseada em Problemas/normas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...